Plant Name: Eremophila oppositifolia
Taxonomic Information:
Plant ID: NPO29441
Plant Latin Name: Eremophila oppositifolia
Taxonomy Genus: Eremophila
Taxonomy Family: Scrophulariaceae
Plant External Links:
NCBI TaxonomyDB:
n.a.
Plant-of-the-World-Online:
n.a.
Geographical Distribution
See the Plant Occurrence Worldwide with Latitude and Longitude Available
Collective Molecular Activities of the Plant
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| DRD1; DRD2; | |
| SLC22A2; | |
| F3; LMNA; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Target Proteins
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
| Cytochrome P450 family 2 | CYP2D6 | Cytochrome P450 2D6 | P10635 | CHEMBL289 |
| Cytochrome P450 family 2 | CYP2C19 | Cytochrome P450 2C19 | P33261 | CHEMBL3622 |
| Cytochrome P450 family 2 | CYP2C9 | Cytochrome P450 2C9 | P11712 | CHEMBL3397 |
| Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
| SLC superfamily of solute carriers | SLC22A2 | Solute carrier family 22 member 2 | O15244 | CHEMBL1743122 |
| Small molecule receptor (family A GPCR) | DRD1 | Dopamine D1 receptor | P21728 | CHEMBL2056 |
| Small molecule receptor (family A GPCR) | DRD2 | Dopamine D2 receptor | P14416 | CHEMBL217 |
| Unclassified | F3 | Coagulation factor III | P13726 | CHEMBL4081 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 1.789E-11 | 9.739E-08 | CYP1A2, CYP2C19, CYP2C9, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0070989; oxidative demethylation | 1.789E-11 | 9.739E-08 | CYP1A2, CYP2C9, CYP2D6, CYP3A4 |
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 1.363E-11 | 9.739E-08 | CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 3.996E-10 | 1.450E-06 | CYP1A2, CYP2C9, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0006805; xenobiotic metabolic process | 1.613E-09 | 3.025E-06 | CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0008395; steroid hydroxylase activity | 1.667E-09 | 3.025E-06 | CYP2C19, CYP2C9, CYP2D6, CYP3A4 |
| MF | GO:0005488; binding | GO:0020037; heme binding | 2.899E-09 | 4.508E-06 | CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4 |
| MF | GO:0005488; binding | GO:0005506; iron ion binding | 8.926E-09 | 1.023E-05 | CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 1.197E-08 | 1.241E-05 | CYP1A2, CYP2C19, CYP2C9 |
| BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 1.322E-07 | 1.152E-04 | CYP1A2, CYP2C19, CYP2C9 |
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 1.760E-07 | 1.369E-04 | CYP1A2, CYP2D6, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0009822; alkaloid catabolic process | 7.235E-07 | 5.251E-04 | CYP2D6, CYP3A4 |
| CC | GO:0016020; membrane | GO:0005789; endoplasmic reticulum membrane | 2.059E-06 | 1.401E-03 | CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4, DRD1 |
| BP | Unclassified; | GO:0021853; cerebral cortex GABAergic interneuron migration | 2.410E-06 | 1.500E-03 | DRD1, DRD2 |
| CC | GO:0016020; membrane | GO:0031090; organelle membrane | 5.223E-06 | 2.774E-03 | CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4, DRD1, DRD2, LMNA |
| BP | GO:0023052; signaling | GO:0051584; regulation of dopamine uptake involved in synaptic transmission | 6.743E-06 | 3.415E-03 | DRD1, DRD2 |
| BP | GO:0032501; multicellular organismal process | GO:0030432; peristalsis | 1.083E-05 | 5.127E-03 | DRD1, DRD2 |
| BP | GO:0032502; developmental process | GO:0021756; striatum development | 1.323E-05 | 6.132E-03 | DRD1, DRD2 |
| BP | GO:0051179; localization | GO:0015872; dopamine transport | 1.588E-05 | 6.779E-03 | DRD1, SLC22A2 |
| BP | GO:0007610; behavior | GO:0007625; grooming behavior | 1.588E-05 | 6.779E-03 | DRD1, DRD2 |
| MF | GO:0060089; molecular transducer activity | GO:0004952; dopamine neurotransmitter receptor activity | 1.588E-05 | 6.779E-03 | DRD1, DRD2 |
| BP | GO:0050896; response to stimulus | GO:0060134; prepulse inhibition | 1.876E-05 | 7.427E-03 | DRD1, DRD2 |
| BP | GO:0009987; cellular process | GO:0060158; phospholipase C-activating dopamine receptor signaling pathway | 1.876E-05 | 7.427E-03 | DRD1, DRD2 |
| MF | GO:0005488; binding | GO:0035240; dopamine binding | 1.876E-05 | 7.427E-03 | DRD1, DRD2 |
| BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 6.750E-17 | 1.470E-12 | CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4 |
| CC | GO:0043226; organelle | GO:0097730; non-motile cilium | 1.187E-04 | 3.356E-02 | DRD1, DRD2 |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10 KEGG Pathways (ordered by adjusted p-value)
Detailed Information of Enriched KEGG Pathways
| Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|---|
| 09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00982 | Drug metabolism - cytochrome P450 | 1.048E-10 | 3.250E-09 | CYP2C9, CYP2D6, CYP1A2, CYP3A4, CYP2C19 |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00591 | Linoleic acid metabolism | 7.439E-10 | 1.153E-08 | CYP2C9, CYP1A2, CYP3A4, CYP2C19 |
| 09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 3.373E-08 | 3.486E-07 | CYP2C9, CYP2D6, CYP1A2, CYP3A4 |
| 09160 Human Diseases | 09161 Cancers | hsa05204 | Chemical carcinogenesis | 5.409E-08 | 4.192E-07 | CYP2C9, CYP1A2, CYP3A4, CYP2C19 |
| 09100 Metabolism | 09108 Metabolism of cofactors and vitamins | hsa00830 | Retinol metabolism | 3.868E-06 | 2.398E-05 | CYP2C9, CYP1A2, CYP3A4 |
| 09150 Organismal Systems | 09156 Nervous system | hsa04726 | Serotonergic synapse | 1.994E-05 | 1.030E-04 | CYP2C9, CYP2D6, CYP2C19 |
| 09160 Human Diseases | 09164 Substance dependence | hsa05030 | Cocaine addiction | 2.613E-04 | 1.157E-03 | DRD1, DRD2 |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00590 | Arachidonic acid metabolism | 4.187E-04 | 1.442E-03 | CYP2C9, CYP2C19 |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00140 | Steroid hormone biosynthesis | 3.664E-04 | 1.420E-03 | CYP1A2, CYP3A4 |
| 09140 Cellular Processes | 09144 Cellular community - eukaryotes | hsa04540 | Gap junction | 8.418E-04 | 2.610E-03 | DRD1, DRD2 |
| Unclassified | Unclassified | hsa01100 | Metabolic pathways | 2.276E-03 | 5.426E-03 | CYP2C9, CYP1A2, CYP2C19, CYP3A4 |
| 09150 Organismal Systems | 09156 Nervous system | hsa04728 | Dopaminergic synapse | 1.796E-03 | 5.061E-03 | DRD1, DRD2 |
| 09160 Human Diseases | 09163 Neurodegenerative diseases | hsa05012 | Parkinson's disease | 2.170E-03 | 5.426E-03 | DRD1, DRD2 |
| 09160 Human Diseases | 09164 Substance dependence | hsa05034 | Alcoholism | 3.419E-03 | 7.067E-03 | DRD1, DRD2 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04024 | cAMP signaling pathway | 4.206E-03 | 8.149E-03 | DRD1, DRD2 |
| 09100 Metabolism | 09110 Biosynthesis of other secondary metabolites | hsa00232 | Caffeine metabolism | 2.498E-03 | 5.531E-03 | CYP1A2 |
Human Diseases Associated with the Target Proteins of the Plant
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
|---|---|---|---|
| NA: NA | Malignant essential hypertension | NA | DRD2; |
| NA: NA | Malignant phaeochromocytoma | NA | DRD2; |
| NA: NA | Inflammatory diseases | NA | DRD2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depressive disorder | F32, F33, M32 | DRD2; |
| A00-B99: Certain infectious and parasitic diseases | Malaria | B54 | CYP2D6; |
| NA: NA | Itching | NA | DRD2; |
| H00-H59: Diseases of the eye and adnexa | Ophthalmic disease | H00-H59 | DRD2; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Acromegaly | E22.0 | DRD2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Substance dependence | F10-F19 | DRD1; DRD2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Alcohol use disorders | F10.2 | DRD2; |
| J00-J99: Diseases of the respiratory system | Bronchitis | J20-J21, J42 | DRD2; |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | DRD1; DRD2; |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | F3; |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | DRD1; DRD2; |
| D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Idiopathic thrombocytopenic purpura | D69.3 | DRD2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Schizophrenia | F20 | DRD1; DRD2; |
| A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | DRD2; |
| NA: NA | Peripheral vasoconstriction | NA | DRD2; |
| NA: NA | Schizoaffective disorders | NA | DRD2; |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | DRD2; |
| I00-I99: Diseases of the circulatory system | Maintain blood pressure in hypotensive states | I10 | DRD2; |
| O00-O9A: Pregnancy, childbirth and the puerperium | Postpartum haemorrhage | O72 | DRD2; |
| I00-I99: Diseases of the circulatory system | Hypotension | I95 | DRD2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | DRD2; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Fibrosis | L90.5 | DRD2; |
| C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | DRD2; |
| NA: NA | False perceptions | NA | DRD2; |
| NA: NA | Corneal vascularity | NA | DRD2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Huntington's disease | F02.2, G10 | DRD2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CYP2D6; DRD2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychosis | F20-F29 | DRD2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychiatric disorder | F01-F99 | DRD1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychotic disorders | F20-F29 | DRD1; DRD2; |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | DRD2; |
| NA: NA | Vomiting | NA | DRD2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Advanced stage Parkinson's disease | F02.3, G20 | DRD2; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | DRD1; |
| NA: NA | Hyperaemia | NA | DRD2; |
| I00-I99: Diseases of the circulatory system | Cardiac failure | I50 | DRD2; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Allergy | T78.4 | DRD2; |
| I00-I99: Diseases of the circulatory system | Cerebrovascular ischaemia | I61-I63 | DRD2; |
| I00-I99: Diseases of the circulatory system | Pulmonary hypertension | I27.0, I27.2 | DRD2; |
| J00-J99: Diseases of the respiratory system | Adult respiratory distress syndrome | J80 | F3; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperprolactinemia | E22.1 | DRD2; |
| J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | DRD2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | DRD1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cocaine addiction | F14.2 | DRD1; |
| I00-I99: Diseases of the circulatory system | Hypertension | I10-I16 | DRD1; DRD2; |
| K00-K95: Diseases of the digestive system | Dermal necrosis | K05 | DRD2; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Depressive fatigue | R53.82 | DRD2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Dementia | F01-F07 | DRD1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Sexual dysfunction | F52 | DRD2; |
| I00-I99: Diseases of the circulatory system | Bleeding | I74, I80-I82 | F3; |
| NA: NA | Benign prostatic hypertrophy | NA | DRD2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Bipolar disorder | F31, F40-F42 | DRD2; |
| C00-D49: Neoplasms | Breast cancer | C50 | DRD2; |
| K00-K95: Diseases of the digestive system | Gastrointestinal problems | K30-K31, Q40-Q41 | DRD2; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Carcinoid syndrome | E34.0 | DRD2; |
| I00-I99: Diseases of the circulatory system | Angina pectoris | I20 | DRD2; |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | DRD2; |
| K00-K95: Diseases of the digestive system | Inflammatory bowel disease | K50, K51 | DRD2; |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | DRD2; |
| I00-I99: Diseases of the circulatory system | Cardiotonic | I50 | DRD2; |
| G00-G99: Diseases of the nervous system G00-G99 | Migraine headaches | G43 | DRD2; |
| G00-G99: Diseases of the nervous system G00-G99 | Migraine | G43 | CYP2D6; |
| O00-O9A: Pregnancy, childbirth and the puerperium | Excessive bleeding following childbirth and spontaneous or elective abortion | O04 | DRD1; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Emesis | R11 | DRD2; |
| J00-J99: Diseases of the respiratory system | Nasal congestion | J34.89 | DRD2; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Nausea | R11 | DRD2; |
>> Profiles of ingredients and activity landscape
>> Targets derived from weak experimental activities
